Jaquinus Tofacitinib Tablets Pharmacodynamics
Mechanism of Action
Jaquinus Tofacitinib tablets is a potent, selective inhibitor of the Janus kinase family with high selectivity against other kinases in the human genome. Tofacitinib inhibits Janus kinases 1, 2, 3 and, to a lesser extent, tyrosine kinase 2. It preferentially inhibits signal transduction of heterodimeric receptors associated with Janus kinase-3 and/or Janus kinase-1. This leads to modulation of diverse aspects of the immune response and attenuation of signal transduction by proinflammatory cytokines.
Treatment with Jaquinus Tofacitinib tablets leads to dose-dependent changes in circulating immune cells. These changes usually resolve after therapy cessation. The treatment is accompanied by a rapid decrease in serum C-reactive protein (C-RP), persisting even after discontinuation. Similar changes are observed in patients with psoriasis.
Jaquinus Tofacitinib tablets are indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ulcerative colitis in adult patients with inadequate response to other therapies.
Jaquinus Tofacitinib tablets are contraindicated in patients with hypersensitivity to tofacitinib, severe hepatic impairment, hepatitis B and/or C infection, creatinine clearance less than 40 ml/min, and concomitant use with certain medications. It is also contraindicated in lactase deficiency, pregnancy, breastfeeding, children under 18, and in certain medical conditions.
Dosage and Administration
Jaquinus Tofacitinib tablets are taken orally, irrespective of meals. Dosage varies depending on the indication. Patients with renal or hepatic impairment may require dose adjustments. The drug should be used cautiously with certain inhibitors and inducers of cytochrome P450 enzymes. Dosing recommendations for specific indications are provided.
Special Patient Categories
Special considerations are given for patients with renal dysfunction and impaired hepatic function. Dose adjustments are recommended based on the severity of impairment. Patients over 65 years of age generally do not require dose adjustments.
Concomitant Use with CYP3A4 Inhibitors and Inducers
Jaquinus Tofacitinib tablets’ dosing may need to be adjusted when used concurrently with strong CYP3A4 inhibitors or inducers. Recommendations are provided for various indications.
Plaque Psoriasis in Japanese and Korean Patients
Patients of Japanese and Korean nationalities have an increased risk of herpes zoster. Consider using a reduced dose of 5 mg twice daily in these patients.
Elderly Patients (>65 years)
No dose adjustment is required in patients aged 65 years or older.